Skip to content


  • Poster presentation
  • Open Access

PReS-FINAL-2274: Antiadalimumab antibodies in pediatric rheumatology patients. A pilot experience

  • 1,
  • 1,
  • 1,
  • 2,
  • 3 and
  • 1
Pediatric Rheumatology201311 (Suppl 2) :P264

  • Published:


  • Visual Analogue Scale
  • Uveitis
  • Adalimumab
  • Median Survival Time
  • Pilot Experience


Immunogenicity of anti-Tumor Necrosis Factor agents is one of the mechanisms behind treatment failure.


To explore the relationship between the presence of antiadalimumab antibodies (AAA), the disease activity and the therapeutic decisions.


Cross-sectional retrospective study determining: 1) serum adalimumab (Ada) levels by a capture ELISA (positive > 5 ng/ml) and 2) levels of AAA by a two-site bridging ELISA [positive > 10 Arbitrary Units (AU)/ml]. The clinical activity was assessed by conventional tests and the physician visual analogue scale (ph-VAS) of 0 to 10, the same day that the blood sample was collected. Blood samples were obtained a few hours before drug administration.


Until March 2013 measurements in 25 patients were available, 15 (60%) of them had some activity of their disease ph-VAS = 1.7 ± 0.9 (1-4). Eight (32%) children presented AAA, range from 12 to 30,000 AU/ml, and absence of Ada levels. All cases with AAA positives had active disease, except one who had received a periocular corticosteroid injection in the previous month. Furthermore 8/17 (47%) patients without AAA had active disease. The duration disease and the age were not different between those with and without AAA. The only clinical and analytical difference was the higher frequency of active uveitis when AAA were present (p = 0.01). Similarly median survival time on treatment was shorter when AAA were present (2.3 vs 2.5 years) (p = 0.03).


Antiadalimumab antibodies appear to explain half of the cases of active disease and their presence is associated with discontinuation of treatment.

Disclosure of interest

None declared.
Table 1

Characteristics of 25 children with pediatric rheumatic diseases treated with Adalimumab.






Active uveitis




Drug switching


n = 8

6 (75)

4 (50)

4 (50)

8 (100)

6 (75)

2 (25)

2 (25)

4 (50)


n = 17

13 (77)

15 (88)

6 (35)

13 (77)

3 (18)

5 (29)

6 (35)

4 (24)

Data are expressed as n (%)

AAA = Antiadalimumab antibodies; JIA = Juvenile Idiopathic Arthritis; ANA = Antinuclear antibodies; MTX = Concomitant Methotrexate.

Authors’ Affiliations

Pediatric Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Immunology, Hospital Universitario La Paz, Madrid, Spain
Ophthalmology, Hospital Universitario La Paz, Madrid, Spain


© Murias Loza et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.